These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36656298)

  • 21. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
    Overeem LH; Lange KS; Fitzek MP; Siebert A; Steinicke M; Triller P; Hong JB; Reuter U; Raffaelli B
    Front Neurol; 2023; 14():1154420. PubMed ID: 37034092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan.
    Wang YF; Yang FC; Chen LA; Chang TY; Su HC; Yang CP; Tu YH; Tzeng YS; Chen SP; Fuh JL; Lai KL; Ling YH; Chen WT; Wang SJ
    Eur J Neurol; 2024 Jun; ():e16372. PubMed ID: 38837528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
    Moskatel LS; Graber-Naidich A; He Z; Zhang N
    Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.
    Yang CP; Zeng BY; Chang CM; Shih PH; Yang CC; Tseng PT; Wang SJ
    Neurotherapeutics; 2021 Oct; 18(4):2639-2650. PubMed ID: 34580838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
    Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study.
    Alpuente A; Gallardo VJ; Caronna E; Torres-Ferrús M; Pozo-Rosich P
    Eur J Neurol; 2021 Jul; 28(7):2378-2382. PubMed ID: 33730441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
    Barbanti P; Aurilia C; Egeo G; Proietti S; Torelli P; d'Onofrio F; Carnevale A; Tavani S; Orlando B; Fiorentini G; Colombo B; Filippi M; Bonassi S; Cevoli S;
    J Neurol; 2024 May; 271(5):2605-2614. PubMed ID: 38342785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study.
    Montisano DA; Giossi R; Canella M; Altamura C; Marcosano M; Vernieri F; Raggi A; Grazzi L
    Toxins (Basel); 2024 Apr; 16(4):. PubMed ID: 38668603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
    Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab.
    Talbot J; Stuckey R; Wood N; Gordon A; Crossingham G; Weatherby S
    Eur J Hosp Pharm; 2024 Jan; ():. PubMed ID: 38182276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
    Curone M; Tullo V; Didier HA; Bussone G
    Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series.
    Toni T; Tamanaha R; Newman B; Liang Y; Lee J; Carrazana E; Vajjala V; Viereck J; Liow KK
    Neurol Sci; 2021 Dec; 42(12):5373-5376. PubMed ID: 34409517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
    Hyeraci G; Paoletti O; Iannone LF; Gini R; De Cesaris F; Geppetti P; Roberto G
    Headache; 2023; 63(10):1391-1402. PubMed ID: 37830925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A; Vaughn C; Rayhill M
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
    Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
    Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
    Muñoz-Vendrell A; Campoy S; Caronna E; Alpuente A; Torres-Ferrus M; Nieves Castellanos C; Olivier M; Campdelacreu J; Prat J; Camiña Muñiz J; Molina Martínez FJ; Mínguez-Olaondo A; Ruibal Salgado M; Santos Lasaosa S; Navarro Pérez MP; Morollón N; López Bravo A; Cano Sánchez LM; García-Sánchez SM; García-Ull J; Rubio-Flores L; Gonzalez-Martinez A; Quintas S; Echavarría Íñiguez A; Gil Luque S; Castro-Sánchez MV; Adell Ortega V; García Alhama J; Berrocal-Izquierdo N; Belvís R; Díaz-Insa S; Pozo-Rosich P; Huerta-Villanueva M
    J Headache Pain; 2023 Jun; 24(1):63. PubMed ID: 37268904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
    Drellia K; Kokoti L; Deligianni CI; Papadopoulos D; Mitsikostas DD
    Cephalalgia; 2021 Jun; 41(7):851-864. PubMed ID: 33567891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine.
    Guerzoni S; Baraldi C; Pani L
    Neurol Sci; 2022 Sep; 43(9):5687-5695. PubMed ID: 35680766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.
    Straube A; Broessner G; Gaul C; Hamann X; Hipp J; Kraya T; Neeb L
    J Headache Pain; 2023 May; 24(1):59. PubMed ID: 37221478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.